- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02653443
A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study
A Randomized, Multi-center, Open-label, Paired Controlled, Crossover In Vivo Study to Assess the Recovery and Lifespan of Radiolabeled Autologous INTERCEPT Treated Apheresis Platelet Components Suspended in Nominal 35% Plasma and 65% InterSol Stored for 6 or 7 Days
Study Overview
Status
Conditions
Detailed Description
For each of the 2 study donation periods, this study will have the following procedures: single or double dose platelet apheresis collection, pathogen inactivation with INTERCEPT Blood System treatment, storage for 6 or 7 days (depending on the period and randomization scheme) at 20°C to 24°C with agitation, collection of "fresh" autologous platelets, radiolabeling, infusion of fresh and stored INTERCEPT Blood System-treated radiolabeled autologous platelets, and collection of blood samples for assessment of platelet recovery and survival (lifespan). There will be a minimum wash-out period of two weeks between the two study periods.
Apheresis platelets will be collected using the Amicus separator and stored for 6 or 7 days (depending on the period and randomization scheme) in 35% plasma/65% InterSol.
Procedures will be as follows: On Day 0, each healthy volunteer subject has apheresis platelets collected. INTERCEPT Blood System treatment will begin on either the day of donation (Day 0) or the day following donation (Day 1) and will be completed within 24 hours after collection. Platelets will then be stored for 6 or 7 days after collection (depending on the period and randomization scheme) at 22°C ±2°C with agitation. Aliquots for in vitro platelet function will be taken on Day 0/1 before INTERCEPT Blood System treatment and on Day 6 or 7. On Day 6 or 7, healthy volunteers will return to the site, and 43 mL of blood will be drawn into a syringe containing 9 mL of Anticoagulant Citrate Dextrose Solution, Formula A (ACD-A). Fresh platelets will be prepared from this sample. An aliquot (10-20 mL) of the stored INTERCEPT Blood System for platelets will be aseptically removed from each subject's test container.
Previously stored (Test) and fresh (Control) platelets will be radiolabeled according to randomization assignment with either Chromium-51 (51Cr) (≤20 μCi) as sodium radiochromate (Na251CrO4) or Indium-111 (111In) (≤15 μCi) as indium oxine, following the labeling and washing procedures outlined by the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The isotope labels will be assigned randomly with equal probability that fresh platelets and stored INTERCEPT Blood System for platelets will be labeled with each isotope., and the same randomization assignment of isotope labels will be utilized for both donation periods for the same subject. Aliquots of the fresh and stored platelets will be radiolabeled in tubes with the standard techniques. After radiolabeling, the autologous fresh and stored INTERCEPT Blood System for platelets will be simultaneously infused into the subject (approximately 10-30 mL). Negative pregnancy test for females of childbearing potential are required before infusion.
Blood samples for radioactivity measurements will be drawn immediately before infusion and at approximately 0, 0.5, 1, and 2 hours post-infusion, and then 6 more samples will be drawn at 1, 2, 3, 4 (or 6), 7, and 11±1 days post-infusion, at approximately the same time of day as the radiolabeled platelet infusion was administered (±4 hours).
Patients will be monitored for safety (adverse events) from the beginning of the study until 10 days following the infusion of radiolabelled platelets in period 2.
Radioactivity measurements Samples will be obtained from the radiolabeled fresh and stored INTERCEPT Blood System for platelets before infusion and used as a radioactive standard. By measuring the volume infused, the total dose of radioactivity infused will be calculated. In vitro elution of the label from the transfused platelets will be determined by the BEST elution assessment method, as well as the in vivo elution of radioactivity from the serial blood samples obtained post-infusion of the labeled platelets.
The standard as well as the subject's whole-blood samples will be corrected for elution and also for the residual activity in the cellular fraction one day after the infusion. Data points 24 hours post-infusion will be used to calculate in vivo recovery after all radioactive corrections have been made. The radioactivity of the samples will be determined by use of a gamma counter. A multiple-hit model will be used to estimate the survival of the radioactively labeled platelets.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New Hampshire
-
Lebanon, New Hampshire, United States, 03766
- Dartmouth-Hitchcock Medical Center
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- Hoxworth Blood Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Normal health status (as determined by the Investigator review of medical history and blood donor physical exam)
- Meet FDA, American Association of Blood Banks (AABB), and site guidelines for blood donation or apheresis platelet donation
- Complete blood count (CBC) and serum chemistry values within established reference ranges or within guidelines as above.
- Pre-donation platelet count of more than 150×10^9 platelets/L
- Negative blood donor screening test panel for Human Immunodeficiency virus (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human T-Lymphotropic virus (HTLV), syphilis, and West Nile virus (WNV)
- Male and female subjects of childbearing potential must agree to use a medically acceptable method of contraception throughout the study. A barrier method of contraception must be included, regardless of other methods.
- Signed and dated informed consent form
Exclusion Criteria:
- Clinically significant acute or chronic disease (as determined by the Investigator)
- Pregnant or nursing females
- Male or female subjects of childbearing potential not using effective contraception
- Disease states or conditions that preclude blood donation or apheresis platelet donation per AABB reference standards
- Treatment with aspirin or aspirin-containing medications within 7 days of apheresis or treatment with non-steroidal anti inflammatory drugs (NSAID), anti-platelet agents or other drugs affecting platelet viability within 3 days of apheresis (e.g. ibuprofen or other NSAIDs)
- Subject received platelet inhibitor within 14 days of donation (e.g. clopidogrel, ticlopidine)
- Splenectomized subjects
- History of known hypersensitivity to indium or chromium
- Participation in another clinical study currently or within the past 28 days
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Day 6
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
|
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
|
Experimental: Day 7
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
|
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL).
Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Post infusion recovery of the Test platelets compared to fresh platelets.
Time Frame: 16 Days
|
16 Days
|
Post infusion recovery of the Test platelets compared to fresh platelets.
Time Frame: 17 Days
|
17 Days
|
Post infusion lifespan of Test platelets compared to fresh platelets.
Time Frame: 16 Days
|
16 Days
|
Post infusion lifespan of Test platelets compared to fresh platelets.
Time Frame: 17 Days
|
17 Days
|
Adverse events: any untold medical occurrence in a subject or clinical investigation subject administered an investigational product and which does not necessarily have a causal relationship with this treatment.
Time Frame: 16 Days
|
16 Days
|
Adverse events: any untold medical occurrence in a subject or clinical investigation subject administered an investigational product and which does not necessarily have a causal relationship with this treatment.
Time Frame: 17 Days
|
17 Days
|
Body Mass Index (kg/m^2)
Time Frame: 16 Days
|
16 Days
|
Body Mass Index (kg/m^2)
Time Frame: 17 Days
|
17 Days
|
Hematocrit (g/dL)
Time Frame: 16 Days
|
16 Days
|
Hematocrit (g/dL)
Time Frame: 17 Days
|
17 Days
|
Hemoglobin (g/dL)
Time Frame: 16 Days
|
16 Days
|
Hemoglobin (g/dL)
Time Frame: 17 Days
|
17 Days
|
Red Blood Cell Count (x10^12/L)
Time Frame: 16 Days
|
16 Days
|
Red Blood Cell Count (x10^12/L)
Time Frame: 17 Days
|
17 Days
|
Platelet Count (×10^3μL)
Time Frame: 16 Days
|
16 Days
|
Platelet Count (×10^3μL)
Time Frame: 17 Days
|
17 Days
|
White Blood Cell Count - with Differential (x10^9/L)
Time Frame: 16 Days
|
16 Days
|
White Blood Cell Count - with Differential (x10^9/L)
Time Frame: 17 Days
|
17 Days
|
Blood Urea Nitrogen (mg/dL)
Time Frame: 16 Days
|
16 Days
|
Blood Urea Nitrogen (mg/dL)
Time Frame: 17 Days
|
17 Days
|
Calcium (mg/dL)
Time Frame: 16 Days
|
16 Days
|
Calcium (mg/dL)
Time Frame: 17 Days
|
17 Days
|
Chloride (mEq/L)
Time Frame: 16 Days
|
16 Days
|
Chloride (mEq/L)
Time Frame: 17 Days
|
17 Days
|
Creatinine (mg/dL)
Time Frame: 16 Days
|
16 Days
|
Creatinine (mg/dL)
Time Frame: 17 Days
|
17 Days
|
Glucose (mg/dL)
Time Frame: 16 Days
|
16 Days
|
Glucose (mg/dL)
Time Frame: 17 Days
|
17 Days
|
Potassium (mEq/L)
Time Frame: 16 Days
|
16 Days
|
Potassium (mEq/L)
Time Frame: 17 Days
|
17 Days
|
Sodium (mEq/L)
Time Frame: 16 Days
|
16 Days
|
Sodium (mEq/L)
Time Frame: 17 Days
|
17 Days
|
Post infusion recovery of the platelets at Day 6 platelets compared to Day 7 platelets.
Time Frame: 16 Days
|
16 Days
|
Post infusion recovery of the platelets at Day 6 platelets compared to Day 7 platelets.
Time Frame: 17 Days
|
17 Days
|
Post infusion lifespan of the platelets at Day 6 platelets compared to Day 7 platelets.
Time Frame: 16 Days
|
16 Days
|
Post infusion lifespan of the platelets at Day 6 platelets compared to Day 7 platelets.
Time Frame: 17 Days
|
17 Days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
pH (pH)
Time Frame: 16 Days
|
16 Days
|
pH (pH)
Time Frame: 17 Days
|
17 Days
|
Platelet count (×10^3/μL)
Time Frame: 16 Days
|
16 Days
|
Platelet count (×10^3/μL)
Time Frame: 17 Days
|
17 Days
|
Platelet dose (×10^11 cells/component)
Time Frame: 16 Days
|
16 Days
|
Platelet dose (×10^11 cells/component)
Time Frame: 17 Days
|
17 Days
|
Mean platelet volume (MPV) (fL)
Time Frame: 16 Days
|
16 Days
|
Mean platelet volume (MPV) (fL)
Time Frame: 17 Days
|
17 Days
|
Morphology score (Kunicki Score)
Time Frame: 16 Days
|
16 Days
|
Morphology score (Kunicki Score)
Time Frame: 17 Days
|
17 Days
|
Component volume (mL)
Time Frame: 16 Days
|
16 Days
|
Component volume (mL)
Time Frame: 17 Days
|
17 Days
|
Glucose (mmol/L)
Time Frame: 16 Days
|
16 Days
|
Glucose (mmol/L)
Time Frame: 17 Days
|
17 Days
|
Lactate (mmol/L)
Time Frame: 16 Days
|
16 Days
|
Lactate (mmol/L)
Time Frame: 17 Days
|
17 Days
|
pO2 (mm Hg)
Time Frame: 16 Days
|
16 Days
|
pO2 (mm Hg)
Time Frame: 17 Days
|
17 Days
|
pCO2 (mm Hg)
Time Frame: 16 Days
|
16 Days
|
pCO2 (mm Hg)
Time Frame: 17 Days
|
17 Days
|
Bicarbonate (HCO3-) (mmol/L)
Time Frame: 16 Days
|
16 Days
|
Bicarbonate (HCO3-) (mmol/L)
Time Frame: 17 Days
|
17 Days
|
Lactate dehydrogenase (IU/L)
Time Frame: 16 Days
|
16 Days
|
Lactate dehydrogenase (IU/L)
Time Frame: 17 Days
|
17 Days
|
Hypotonic Shock Response (HSR) (%)
Time Frame: 16 Days
|
16 Days
|
Hypotonic Shock Response (HSR) (%)
Time Frame: 17 Days
|
17 Days
|
Extent of Shape Change (ESC) (%)
Time Frame: 16 Days
|
16 Days
|
Extent of Shape Change (ESC) (%)
Time Frame: 17 Days
|
17 Days
|
p-selectin expression (CD62) (% activation)
Time Frame: 16 Days
|
16 Days
|
p-selectin expression (CD62) (% activation)
Time Frame: 17 Days
|
17 Days
|
Adenosine 5'-Triphosphate (ATP) (nmol/10^8 platelets)
Time Frame: 16 Days
|
16 Days
|
Adenosine 5'-Triphosphate (ATP) (nmol/10^8 platelets)
Time Frame: 17 Days
|
17 Days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CLI 00116
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet